Status:
COMPLETED
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
Lead Sponsor:
Pfizer
Conditions:
Hypercholesterolemia
Dyslipidemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational...
Eligibility Criteria
Inclusion
- LDL-C must be greater or equal to 130 mg/dl
- BMI must be between 18.5 and 40 kg/m2
- Japanese volunteers must have 4 Japanese grand parents born in Japan
Exclusion
- History of cardiovascular or cerebrovascular event during the past year.
- Poorly controlled type 1 or type 2 diabetes mellitus
- Subjects who have taken lipid lowering therapies within the last 3 months of screening.
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT01243151
Start Date
February 1 2011
End Date
October 1 2011
Last Update
January 22 2019
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
California Clinical Trials Medical Group
Culver City, California, United States, 90232
2
Glendale Adventist Medical Center
Glendale, California, United States, 91206
3
SeaView Research, Inc.
Miami, Florida, United States, 33126
4
SeaView Research, Inc.
Miami, Florida, United States, 33134